Yttrium-90 Radioembolization for Intrahepatic Cholangiocarcinoma: Non-University Tertiary Care Center Experience.

IF 1.2 4区医学 Q3 SURGERY

Surgical Innovation Pub Date : 2025-06-01 Epub Date: 2025-01-30 DOI:10.1177/15533506251317283

Sahar Darian, Juan S Malo, Joseph S Lim, Joseph F Buell, Houssam Osman, Travis Van Meter, D Rohan Jeyarajah

{"title":"Yttrium-90 Radioembolization for Intrahepatic Cholangiocarcinoma: Non-University Tertiary Care Center Experience.","authors":"Sahar Darian, Juan S Malo, Joseph S Lim, Joseph F Buell, Houssam Osman, Travis Van Meter, D Rohan Jeyarajah","doi":"10.1177/15533506251317283","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundIntrahepatic cholangiocarcinoma (ICC) presents a significant clinical challenge due to its high fatality rate and limited surgical candidacy. With only 30-40% of patients eligible for surgery upon diagnosis, alternative therapies are imperative. This study assesses the efficacy of Yttrium-90 (Y-90) radioembolization for unresectable ICC patients in a non-university tertiary care center (NUTCC).MethodsA retrospective analysis of 15 unresectable ICC patients treated with Y-90 radioembolization was conducted. Tumor response, survival, and adverse events were evaluated using RECIST criteria.Results60% of patients exhibited partial response, and 20% showed stable disease, with notable tumor size reduction and a median survival of 14 months. Minimal adverse effects were observed, indicating Y-90's favorable safety profile.ConclusionY-90 radioembolization shows potential in reducing tumor burden and enhancing survival rates with minimal adverse effects for unresectable ICC. Larger prospective studies are needed to confirm its efficacy and define its role in ICC treatment protocols.</p>","PeriodicalId":22095,"journal":{"name":"Surgical Innovation","volume":" ","pages":"229-234"},"PeriodicalIF":1.2000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgical Innovation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15533506251317283","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

BackgroundIntrahepatic cholangiocarcinoma (ICC) presents a significant clinical challenge due to its high fatality rate and limited surgical candidacy. With only 30-40% of patients eligible for surgery upon diagnosis, alternative therapies are imperative. This study assesses the efficacy of Yttrium-90 (Y-90) radioembolization for unresectable ICC patients in a non-university tertiary care center (NUTCC).MethodsA retrospective analysis of 15 unresectable ICC patients treated with Y-90 radioembolization was conducted. Tumor response, survival, and adverse events were evaluated using RECIST criteria.Results60% of patients exhibited partial response, and 20% showed stable disease, with notable tumor size reduction and a median survival of 14 months. Minimal adverse effects were observed, indicating Y-90's favorable safety profile.ConclusionY-90 radioembolization shows potential in reducing tumor burden and enhancing survival rates with minimal adverse effects for unresectable ICC. Larger prospective studies are needed to confirm its efficacy and define its role in ICC treatment protocols.

查看原文本刊更多论文

钇-90放射栓塞治疗肝内胆管癌：非大学三级护理中心经验。

背景：肝内胆管癌（ICC）由于其高致死率和有限的手术选择而提出了重大的临床挑战。只有30-40%的患者有资格在诊断后进行手术，替代疗法势在必行。本研究评估了在非大学三级医疗中心（NUTCC）使用钇-90 （Y-90）放射栓塞治疗不可切除的ICC患者的疗效。方法：对15例行Y-90放射栓塞治疗的不可切除的ICC患者进行回顾性分析。使用RECIST标准评估肿瘤反应、生存和不良事件。结果：60%的患者出现部分缓解，20%的患者病情稳定，肿瘤大小明显缩小，中位生存期为14个月。观察到最小的不良反应，表明Y-90有利的安全性。结论：Y-90放射栓塞治疗不可切除的ICC具有减轻肿瘤负担、提高生存率、不良反应最小的潜力。需要更大规模的前瞻性研究来证实其有效性并确定其在ICC治疗方案中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Surgical Innovation 医学-外科

CiteScore

2.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Surgical Innovation (SRI) is a peer-reviewed bi-monthly journal focusing on minimally invasive surgical techniques, new instruments such as laparoscopes and endoscopes, and new technologies. SRI prepares surgeons to think and work in "the operating room of the future" through learning new techniques, understanding and adapting to new technologies, maintaining surgical competencies, and applying surgical outcomes data to their practices. This journal is a member of the Committee on Publication Ethics (COPE).